Australia's most trusted
source of pharma news
Posted 27 January 2026 AM
Asteri Pharma has added the first biologic and an amyotrophic lateral sclerosis (ALS) treatment to its portfolio under two new partnerships announced in the past month.
Last week, the company revealed it signed a supply, distribution and sublicense agreement with Esteve, an international speciality pharma headquartered in Spain, to provide continued access to Increlex, a biologic product for children and adolescents aged two to 18 with severe primary insulin-like growth factor 1 defiency (SPIGFD).

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.